Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Sekisui Medical Co., Ltd., part of Sekisui Chemical Co., Ltd., is a company headquartered in Tokyo, Japan, that manufactures and markets in-vitro diagnostic substances and pharmaceutical products. Sekisui Chemical Co., Ltd. acquired Sekisui Medical Co., Ltd. from Daiichi Sankyo Co., Ltd. on October 02, 2006.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Chengdu Diao Group Tianfu Pharmaceutical Co., Ltd., established on 1994-03-06, Business range includes tablet,hard capsule,Granules,eye drops,syrup,tincture,mixture,oral solution,pill production;Pharmaceutical Packaging;Three types of Chinese herbal medicines.(The above business scope shall operate within the validity period of the license)*.none.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Maxygen Holdings Ltd. is a Caymanian private company located in George Town. The firm provides investment services.

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adult and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing.

Jinan Bangwen Pharmaceutical Technology Co., Ltd., established on 2015-02-15, Business scope includes medical technology development;Chinese medicine products,Healthy food,Technology development of washing products,Technical Consulting and Technical Services;translation service;office services(Does not include engraved seal);data processing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Xi'an Century Shengkang Pharmaceutical Co., Ltd., established on 2007-05-21, Business scope includes general items:License the project:small volume injection,Production of suppositories,Sales(The drug production license is limited to2025year12moon20day).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)General operating items:Research on Chinese and Western Medicine,Consulting services for medical technology.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shanghai Medical Life Science Research Center Co., Ltd., established on 1998-11-02, Business scope includes biological,medicine,Technology development in the field of medical device technology,technical consulting,technology transfer,Technical Services(genetically modified organism,Except human stem cell genetic diagnosis),Economic Information Consulting(In addition to brokerage).[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

BioCritica is a biotechnology company focused on meeting the critical care needs of patients and clinicians in the hospital market. Simply stated, their mission is to develop and commercialize products that make a dramatic improvement in people's lives. In addition to Xigris for the treatment of severe sepsis, BioCritica is developing a pipeline of other products. The company is headquartered in Indianapolis, IN.

Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada.

Harbin Yew Bio-Pharmaceutical Co., Ltd., established on 2009-08-04, Business scope includes licensed projects:pharmaceutical production;Production of Class II Medical Devices;Production of Class III Medical Devices;Production of hygiene products and single-use medical products;Production of medical masks.General project:Production of Class I Medical Devices;Sales of Class II Medical Devices;Medical Mask Retail;Sales of Class I Medical Devices.

Hengtuo Group Guangxi Shengkang Pharmaceutical Co., Ltd., established on 2004-06-17, The business scope includes hard capsules,tablet,Granules(Contains traditional Chinese medicine pretreatment and extraction)Production and sales(Operate with qualification certificate);food(Specific projects are subject to the approval of the audit department),Healthy food,medical instruments(Operate with qualification certificate),cosmetic,disinfection products,hygiene products,Production and sales of daily necessities;Chinese patent medicine,Chemicals,food,Healthy food,medical instruments,cosmetic,disinfection products,hygiene products,Research and development of daily necessities;Technology transfer and consulting services;Production and sales of labor protection products;crop,Planting and buying and selling of Chinese herbal medicine.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

The 301 Hospital (Chinese: 三〇一医院) or People's Liberation Army General Hospital (Chinese: 中国人民解放军总医院), which constitutes simultaneously the PLA Postgraduate Medical School (Chinese: 中国人民解放军医学院), located in Beijing, China, is a military hospital directly subsidiary to Logistic Support Department of the Central Military Commission and the largest general hospital under the auspices of the People's Liberation Army. Its mission includes assuring the health of PLA and China's leaders.